Factors such as the rising prevalence of type 2 diabetes, higher treatment demand, and increased prescriptions for GLP-1 receptor agonist medications are all contributing to the segment's expansion
GLP-1RAs have clearly defined benefits in metabolic and cardiovascular disorders, and the possibility that they could be beneficial in asthma and neurologic diseases could decrease the use of additional medications and improve quality of life
When you weigh more, every time you take a step, the bone feels its being injured and this stimulates cells called osteoblasts to lay down new bone, she says
The primary concern, rapid drops in blood sugar from GLP-1 therapy can temporarily worsen existing DR, which is why it has been highlighted in research
sPLA 2 could metabolize phospholipids in platelets, erythrocytes, and endothelial cells to produce arachidonic acid and lysophospholipids [349]
DPP-4 inhibitors are not associated with increased CV risk